The Global Personalized Cancer Vaccine Market was valued at USD 216.9 million in 2024 and is estimated to grow at a CAGR of 26.4% to reach USD 2.2 billion by 2034.
This rapid growth is driven by the increasing prevalence of cancer worldwide, coupled with advancements in genomics, precision medicine, and immunotherapy. Next-generation sequencing (NGS) and genomic profiling allow clinicians to identify tumor-specific neoantigens, which are critical for developing patient-specific vaccines. Declining sequencing costs have made these technologies more accessible in clinical practice. Personalized cancer vaccines train a patient’s immune system to recognize and attack their unique cancer cells, offering a targeted alternative to conventional therapies. The rise in cancer cases, aging populations, and growing healthcare expenditure globally are fueling demand, particularly in North America and the Asia-Pacific, where advanced diagnostic and healthcare infrastructure support personalized treatments. These vaccines align with the broader shift toward precision medicine, immunotherapy, and individualized patient care.
The dendritic cell vaccine segment accounted for an 85.5% share in 2024 and is expected to reach USD 1.9 billion by 2034. Dendritic cells are highly effective antigen-presenting cells capable of eliciting strong T-cell responses, making them ideal for personalized cancer vaccines. DC vaccines provide targeted action, minimize off-target effects, and enhance patient outcomes.
The solid tumors segment generated USD 180.9 million in 2024. Solid tumors are central to more than half of ongoing personalized cancer vaccine trials, including melanoma, non-small cell lung cancer, glioblastoma, and pancreatic cancer. Positive clinical outcomes are accelerating regulatory approvals and driving adoption, validating the efficacy of these vaccines in solid tumor treatment.
The hospitals segment is expected to reach USD 1.3 billion by 2034. Hospitals are the primary sites for vaccine administration, patient monitoring, and clinical trials, positioning them as the most trusted and efficient channels for delivering personalized cancer vaccines. Their role in diagnostics and integrated care makes them essential in patient-centric treatment pathways.
North America Personalized Cancer Vaccine Market held a 46.2% share in 2024. The region hosts nearly half of the global clinical trials for these vaccines, focusing on melanoma, NSCLC, and glioblastoma. Major biotech companies are heavily investing in research and development in North America, supported by public-private partnerships, federal grants, and venture capital funding.
Prominent players in the Global Personalized Cancer Vaccine Market include Immunomic Therapeutics, BioNTech, Elicio Therapeutics, Immatics, Takis Biotech, Candel Therapeutics, VacV Biotherapeutics, Agenus, Moderna, OSE Immunotherapeutics, Evaxion Biotech, Dendreon Pharmaceuticals, ImmunityBio, Infinitopes, and Imugene. Companies in the Personalized Cancer Vaccine Market are implementing multiple strategies to strengthen their market position. They are investing heavily in research and development to enhance vaccine efficacy, optimize antigen selection, and improve patient-specific formulations. Strategic collaborations with academic institutions, hospitals, and biotechnology partners help accelerate clinical validation and regulatory approvals. Firms are expanding geographic footprints through partnerships and licensing agreements to access emerging markets. Additionally, they are leveraging digital tools, AI, and genomic analytics to streamline vaccine design and reduce production timelines.
This product will be delivered within 2-4 business days.
This rapid growth is driven by the increasing prevalence of cancer worldwide, coupled with advancements in genomics, precision medicine, and immunotherapy. Next-generation sequencing (NGS) and genomic profiling allow clinicians to identify tumor-specific neoantigens, which are critical for developing patient-specific vaccines. Declining sequencing costs have made these technologies more accessible in clinical practice. Personalized cancer vaccines train a patient’s immune system to recognize and attack their unique cancer cells, offering a targeted alternative to conventional therapies. The rise in cancer cases, aging populations, and growing healthcare expenditure globally are fueling demand, particularly in North America and the Asia-Pacific, where advanced diagnostic and healthcare infrastructure support personalized treatments. These vaccines align with the broader shift toward precision medicine, immunotherapy, and individualized patient care.
The dendritic cell vaccine segment accounted for an 85.5% share in 2024 and is expected to reach USD 1.9 billion by 2034. Dendritic cells are highly effective antigen-presenting cells capable of eliciting strong T-cell responses, making them ideal for personalized cancer vaccines. DC vaccines provide targeted action, minimize off-target effects, and enhance patient outcomes.
The solid tumors segment generated USD 180.9 million in 2024. Solid tumors are central to more than half of ongoing personalized cancer vaccine trials, including melanoma, non-small cell lung cancer, glioblastoma, and pancreatic cancer. Positive clinical outcomes are accelerating regulatory approvals and driving adoption, validating the efficacy of these vaccines in solid tumor treatment.
The hospitals segment is expected to reach USD 1.3 billion by 2034. Hospitals are the primary sites for vaccine administration, patient monitoring, and clinical trials, positioning them as the most trusted and efficient channels for delivering personalized cancer vaccines. Their role in diagnostics and integrated care makes them essential in patient-centric treatment pathways.
North America Personalized Cancer Vaccine Market held a 46.2% share in 2024. The region hosts nearly half of the global clinical trials for these vaccines, focusing on melanoma, NSCLC, and glioblastoma. Major biotech companies are heavily investing in research and development in North America, supported by public-private partnerships, federal grants, and venture capital funding.
Prominent players in the Global Personalized Cancer Vaccine Market include Immunomic Therapeutics, BioNTech, Elicio Therapeutics, Immatics, Takis Biotech, Candel Therapeutics, VacV Biotherapeutics, Agenus, Moderna, OSE Immunotherapeutics, Evaxion Biotech, Dendreon Pharmaceuticals, ImmunityBio, Infinitopes, and Imugene. Companies in the Personalized Cancer Vaccine Market are implementing multiple strategies to strengthen their market position. They are investing heavily in research and development to enhance vaccine efficacy, optimize antigen selection, and improve patient-specific formulations. Strategic collaborations with academic institutions, hospitals, and biotechnology partners help accelerate clinical validation and regulatory approvals. Firms are expanding geographic footprints through partnerships and licensing agreements to access emerging markets. Additionally, they are leveraging digital tools, AI, and genomic analytics to streamline vaccine design and reduce production timelines.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Vaccine Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Indication, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies featured in this Personalized Cancer Vaccine market report include:- BioNTech
- Moderna
- Immatics
- Candel Therapeutics
- Elicio Therapeutics
- Evaxion Biotech
- Immunomic Therapeutics
- Imugene
- Infinitopes
- OSE Immunotherapeutics
- Takis Biotech
- VacV Biotherapeutics
- ImmunityBio
- Agenus
- Dendreon Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | November 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 216.9 Million |
| Forecasted Market Value ( USD | $ 2200 Million |
| Compound Annual Growth Rate | 26.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
